This is BrainsWay’s global website. The global website is not intended for persons in the United States and includes information on clinical indications that were not cleared by the FDA, which are subject to further US regulatory review for safety and efficacy. BrainsWay is cleared by the FDA only for patients with MDD who failed to respond to one or more anti-depressants in the current episode, and for patients with OCD as an adjunct treatment.
As mental health gains greater acceptance in today’s society, more and more people are thankfully getting the help they need—and insurance providers are meeting this demand with an ever-expanding range of therapies covered by their plans, lowering the costs of treatments such as BrainsWay’s transcranial magnetic stimulation, or TMS.
TMS costs vary according to your insurance plan, the condition being treated, and the recommended number of sessions. However, together with its proven desirable impact on mental health conditions, TMS has been found to be cost-effective when compared to other treatment courses.
TMS is covered differently by insurance providers around the world and has been FDA cleared for treating major depressive disorder (MDD) in the U.S. since 2013. In a more recent development, BrainsWay’s TMS treatment was FDA cleared to treat obsessive-compulsive disorder (OCD) in 2018.
Where covered by insurance, patients will typically incur the co-pay per treatment session specified in their insurance plan. Patients should speak with their mental health provider to find out about payment options, as in some cases opportunities to create single case agreements with insurance companies can also cover the treatment cost.
In addition to the U.S., BrainsWay’s TMS treatment is covered throughout Europe and other regions, as an increasing number of insurance providers are looking to meet their clients’ needs by offering coverage for this treatment.
At present, TMS has never been more widely accepted—and readily available—for those who might benefit from it.